VKH
AVEO

Virtu KCG Holdings’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Virtu KCG Holdings’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,622
Closed -$27K – 3748
2017
Q1 		$27K Buy
4,622
+3,268
+241% +$23.6K ﹤0.01% 2944
2016
Q4 		$7K Buy
+1,354
New +$9.03K ﹤0.01% 3313
2016
Q3 		– Sell
-3,497
Closed -$34K – 3650
2016
Q2 		$34K Buy
3,497
+513
+17% +$4.95K ﹤0.01% 2734
2016
Q1 		$27K Sell
2,984
-569
-16% -$5.63K ﹤0.01% 2562
2015
Q4 		$45K Buy
3,553
+2,127
+149% +$25.3K ﹤0.01% 3183
2015
Q3 		$17K Sell
1,426
-1,069
-43% -$15.4K ﹤0.01% 3181
2015
Q2 		$43K Buy
+2,495
New +$44.9K ﹤0.01% 3095
2015
Q1 		– Sell
-7,308
Closed -$61K – 4143
2014
Q4 		$61K Buy
+7,308
New +$66.8K ﹤0.01% 3379
2014
Q1 		– Sell
-5,015
Closed -$92K – 4292
2013
Q4 		$92K Buy
5,015
+3,721
+288% +$74.5K ﹤0.01% 3465
2013
Q3 		$27K Buy
+1,294
New +$29.6K ﹤0.01% 3591

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Virtu KCG Holdings's AVEO Position: Q2 2017 in Review

Virtu KCG Holdings sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2017, closing a stake of 4,622 shares — an estimated $27K sold.

Virtu KCG Holdings first reported a position in AVEO in Q3 2013 and held it in 10 quarters. The position peaked at $92K in Q4 2013. 49 funds tracked by Wall St. Rank hold AVEO as of Q2 2017.

  • Virtu KCG Holdings reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 4,622 AVEO Pharmaceuticals, Inc. shares in Q2 2017, an estimated $27K.
  • Virtu KCG Holdings first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2013 and held it in 10 quarters.
  • Virtu KCG Holdings's AVEO Pharmaceuticals, Inc. position peaked at $92K in Q4 2013.
  • 49 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.